GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Athira Pharma Inc.
Athira Pharma is a biotech company developing drugs to treat Alzheimer's disease. Its stock price is extremely volatile, reflecting both the enormous potential of this market and the high risks and numerous failures of other companies in this field.
Share prices of companies in the market segment - Neuro
Athira Pharma is a biopharmaceutical company developing drugs to restore neural connections and treat neurodegenerative diseases such as Alzheimer's. We've classified it under the "Neurology" category. The chart below shows how the market is evaluating innovative approaches to dementia treatment.
Broad Market Index - GURU.Markets
Athira Pharma is a biotech company developing drugs to restore neural connections in the treatment of Alzheimer's disease. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Athira shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
ATHA - Daily change in the company's share price Athira Pharma Inc.
For Athira Pharma, Inc., which develops Alzheimer's drugs, daily price changes are a measure of enormous volatility. This metric reflects extreme sensitivity to clinical trial data and is key to risk assessment.
Daily change in the price of a set of shares in a market segment - Neuro
Athira Pharma, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with ATHA, which focuses on treating neurodegenerative diseases, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Athira Pharma is a biotech company developing drugs to treat neurodegenerative diseases. Its shares are known for their high volatility, driven by expectations and clinical trial results. This is a prime example of how a single story can create powerful market ripples.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Athira Pharma Inc.
For Athira Pharma, Inc., the year-over-year trend is a story about the development of a drug to treat Alzheimer's disease. Its 12-month market cap is entirely dependent on clinical trial data. Its valuation reflects both the enormous potential for success and the high risks associated with this highly complex field, as well as the past controversies surrounding its data.
Annual dynamics of market capitalization of the market segment - Neuro
Athira Pharma, Inc. is a late-stage biotech developing drugs for the treatment of neurodegenerative diseases. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs in this complex field.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Athira Pharma, focused on Alzheimer's disease, represents one of the riskiest bets in biotech. Its year-over-year performance, compared to the market, features extreme ups and downs based on any news about clinical trials. It's a pure bet on a scientific breakthrough in a field that has seen decades of failure.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Athira Pharma Inc.
Athira is a clinical-stage biotech company targeting Alzheimer's disease. Its monthly performance is entirely dependent on the results of its clinical trials. Data on its drug are binary events, causing sharp fluctuations.
Monthly dynamics of market capitalization of the market segment - Neuro
Athira Pharma is a clinical-stage biopharmaceutical company developing drugs to restore neural connections and treat neurodegenerative diseases, primarily Alzheimer's disease. The chart below shows the overall dynamics in the neuroscience sector, reflecting the hopes and risks associated with finding a cure for this disease.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Alzheimer's drug development is one of the riskiest areas in biotech. The chart below shows the overall risk appetite. Is Athira Pharma moving with the flow, or is its stock solely dependent on clinical trial data?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Athira Pharma Inc.
Athira Pharma develops therapies for neurodegenerative diseases such as Alzheimer's. Its weekly stock performance is a high-stakes story in one of the most complex areas of medicine, where clinical news can cause extreme fluctuations.
Weekly dynamics of market capitalization of the market segment - Neuro
Developing drugs to treat neurodegenerative diseases is a marathon with sprints in between. This chart for Athira Pharma shows how clinical trial news impacts the stock in the short term and how these movements relate to the overall dynamics of the neurosciences sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Athira Pharma is another biotech company whose shares exist in their own universe, reacting to clinical trial data. The chart clearly demonstrates how its weekly performance is isolated from general market fluctuations, following its own unique scientific trajectory.
Market capitalization of the company, segment and market as a whole
ATHA - Market capitalization of the company Athira Pharma Inc.
The Athira Pharma chart is a highly volatile story of Alzheimer's drug development. Its market cap reflects both the enormous potential for success and the high risks associated with clinical trial failures and corporate scandals. It's a visual representation of scientific uncertainty.
ATHA - Share of the company's market capitalization Athira Pharma Inc. within the market segment - Neuro
Athira Pharma is a biotech company developing treatments for neurodegenerative diseases such as Alzheimer's. Its market capitalization in the neurosciences segment reflects the high expectations for its research. The company's weight reflects the success of its innovative approach to restoring neural connections.
Market capitalization of the market segment - Neuro
Athira Pharma aims to restore brain function in neurodegenerative diseases. How big is this hope? The chart below is a barometer of the neuroscience pharmaceutical sector. Its dynamics reflect the complexity and risks of Alzheimer's drug development, where any failure or success triggers violent reactions.
Market capitalization of all companies included in a broad market index - GURU.Markets
Athira Pharma's chart is another dramatic story in the field of neurodegenerative diseases. Its volatile market cap reflects the ups and downs associated with the clinical trials of its Alzheimer's drug. It's a chart that illustrates how the market is desperately searching for a breakthrough in this complex field.
Book value capitalization of the company, segment and market as a whole
ATHA - Book value capitalization of the company Athira Pharma Inc.
The book value of Athira Pharma, which develops therapies for neurodegenerative diseases, is based on its material foundation: laboratories, rights to the technology platform, and financial reserves for clinical trials. The chart below shows how this scientific and financial capital has changed.
ATHA - Share of the company's book capitalization Athira Pharma Inc. within the market segment - Neuro
Athira Pharma, Inc. is a company focused on combating neurodegeneration. Its tangible assets include cutting-edge laboratories and preclinical research centers where new approaches to restoring brain function are being developed. The chart shows the share of this knowledge-intensive R&D infrastructure the company controls in its field.
Market segment balance sheet capitalization - Neuro
Athira Pharma is a biotechnology company. Pharmaceuticals, as the graph shows, are both knowledge- and capital-intensive. Athira focuses on drug development, and its capital is its intellectual property and R&D infrastructure for clinical trials.
Book value of all companies included in the broad market index - GURU.Markets
Athira Pharma's assets are not factories, but capital and laboratory facilities for clinical trials of a new approach to treating Alzheimer's disease, aimed at restoring neural networks. Its book value reflects its financial resources for pursuing these breakthrough, yet risky, developments.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Athira Pharma Inc.
Athira Pharma is another company working on a drug for Alzheimer's disease. Its market capitalization is a pure bet on the success of its scientific approach. The chart shows extreme sensitivity to any clinical trial data, as the potential market is huge, but the risks of failure are extremely high.
Market to book capitalization ratio in a market segment - Neuro
Athira Pharma develops drugs to treat neurodegenerative diseases such as Alzheimer's. The company's value is based on the hope of a scientific breakthrough. The chart shows that its market capitalization is based on its research potential, not its current tangible assets.
Market to book capitalization ratio for the market as a whole
Athira Pharma treats neurodegenerative diseases. Like many biotechs, its market capitalization reflects investor hopes for a future blockbuster, not the current asset value. This chart helps assess the scale of this "hope premium" in the sector compared to the overall market valuation.
Debts of the company, segment and market as a whole
ATHA - Company debts Athira Pharma Inc.
Athira Pharma is a biotech company developing therapies for neurodegenerative diseases such as Alzheimer's. This is one of the most complex and capital-intensive areas of medicine. This chart reflects the company's financial strategy for raising funds to conduct expensive clinical trials in hopes of a scientific breakthrough.
Market segment debts - Neuro
Athira Pharma is a clinical-stage biotech company developing therapies for neurodegenerative diseases such as Alzheimer's. Research in this area is extremely expensive and risky. This chart reflects its financial structure, which relies entirely on equity to fund its research program.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Athira Pharma Inc.
Athira Pharma is also working on drugs for neurodegenerative diseases. This chart reflects its financial structure. In this complex field of medicine, where decades of research can yield no results, debt financing is an extremely risky strategy. Investors monitor this metric as an indicator of financial vulnerability.
Market segment debt to market segment book capitalization - Neuro
Athira Pharma develops treatments for neurodegenerative diseases such as Alzheimer's. This is one of the most complex and capital-intensive areas in biotechnology. The chart shows the sector's overall debt load, highlighting the enormous financial resources Athira requires to carry out its ambitious research.
Debt to book value of all companies in the market
Athira Pharma is a biotech company developing therapies for Alzheimer's disease, one of the most complex and capital-intensive areas of medicine. This chart, reflecting the debt burden of a stable economy, highlights that Athira's funding is a venture bet on a scientific breakthrough, not traditional lending.
P/E of the company, segment and market as a whole
P/E - Athira Pharma Inc.
For Athira Pharma, a biopharmaceutical company working on a drug for Alzheimer's disease, the P/E ratio is irrelevant. The company has no profit, and its valuation is a purely speculative bet on a breakthrough in one of the most complex areas of medicine. Any values on this chart are uninformative.
P/E of the market segment - Neuro
Athira Pharma is a late-stage clinical biotech company specializing in the development of small-molecule drugs to restore neural health and slow neurodegeneration, particularly in Alzheimer's disease. This chart shows the average market value for neuropharmaceuticals, helping to understand how the market views this innovative approach.
P/E of the market as a whole
Athira Pharma is a biotech company developing drugs to treat neurodegenerative diseases such as Alzheimer's. Its valuation is a bet on a breakthrough in one of the most complex areas of medicine. It is unrelated to the overall economic trends shown in this chart and depends solely on clinical trial data.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Athira Pharma Inc.
Athira Pharma is a late-stage biotech company developing drugs to restore neural connections and treat neurodegenerative diseases such as Alzheimer's. This chart reflects investor expectations for clinical trial results. The valuation is based on the potential for a breakthrough in one of the most complex areas of medicine.
%20P%2FE%20Athira%20Pharma%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Athira-Pharma-Inc.&v=1772643578167 "Chart of the company's future (projected) P/E Athira Pharma Inc.")
Future (projected) P/E of the market segment - Neuro
Athira Pharma is a clinical-stage biotech developing therapies for neurodegenerative diseases such as Alzheimer's. Its valuation, compared to other companies in the field, reflects both enormous expectations and risks, demonstrating the level of investor confidence in its unique approach to restoring neural connections.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772643578216 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Athira Pharma develops drugs to treat neurodegenerative diseases such as Alzheimer's. This is one of the most complex and risky areas in pharmaceuticals. This chart reflects investors' overall risk appetite. For companies working on breakthrough but highly risky projects, a positive market environment is crucial for raising capital.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772643578219 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Athira Pharma Inc.
Athira Pharma is a biotech company working to restore neuronal function to treat neurodegenerative diseases such as Alzheimer's. The financial metrics shown in the chart reflect significant investment in cutting-edge science. Success depends entirely on clinical trial results.
Profit of companies in the market segment - Neuro
Athira Pharma is also working on treatments for neurodegenerative diseases, particularly Alzheimer's disease. This chart provides a health indicator for the entire neuroscience biotech segment. It demonstrates whether this area is a breakthrough area or a "graveyard" for expensive clinical trials, which is important for assessing Athira's risks.
Overall market profit
Athira Pharma is developing therapies for neurodegenerative diseases such as Alzheimer's. This is one of the most complex and risky areas in pharmaceuticals. Athira Pharma's success or failure will be determined by the results of clinical trials, not by economic cycles, as this chart illustrates.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Athira Pharma Inc.
Athira Pharma develops treatments for neurodegenerative diseases such as Alzheimer's, one of the most complex areas in medicine. The company's future profit forecast is highly speculative and reflects analysts' hopes for a breakthrough in its research, potentially leading to the development of a sought-after drug.
%20profit%20of%20the%20company%20Athira%20Pharma%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Athira-Pharma-Inc.&v=1772643578335 "Graph of future (projected) profit of the company Athira Pharma Inc.")
Future (predicted) profit of companies in the market segment - Neuro
Athira Pharma is a biotech company developing drugs to restore neural connections and treat neurodegenerative diseases, primarily Alzheimer's disease. This chart shows forecasts for the neurosegment. It provides investors with context for assessing the industry's enormous potential if such breakthrough treatment approaches are successful.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772643578374 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
This chart reflects the overall investment climate. For Athira Pharma, which works on treating neurodegenerative diseases, this is driven by capital availability. During economic growth, investors are more willing to invest in risky but promising biotech projects, while during a downturn, funding becomes scarce.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772643578381 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Athira Pharma Inc.
Athira Pharma is also working on treatments for neurodegenerative diseases, particularly Alzheimer's. Its virtually nonexistent revenue, as seen in this chart, is a clear bet by investors on a scientific breakthrough and a huge potential market for its therapy.
P/S market segment - Neuro
Athira Pharma is a late-stage biopharmaceutical company working on treatments for neurodegenerative diseases such as Alzheimer's. This chart shows the average valuation in the neuroscience sector, reflecting the high expectations and risks associated with drug development in one of the most complex areas of medicine.
P/S of the market as a whole
Athira Pharma, Inc. is a biopharmaceutical company developing a new generation of drugs to restore neural connections in diseases such as Alzheimer's. Its valuation is based on expectations of a breakthrough treatment. This chart, showing the average revenue estimate, illustrates the market premium placed on hope in this highly complex area of medicine.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Athira Pharma Inc.
Athira Pharma develops therapies for neurodegenerative diseases such as Alzheimer's. The company's valuation is based on the expected future success of its drugs. The chart reflects investors' faith in the potential of its scientific approach and the ability to create a breakthrough drug that will generate billions in sales.
%20P%2FS%20Athira%20Pharma%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Athira-Pharma-Inc.&v=1772643578478 "The graph of the company's future (projected) P/S Athira Pharma Inc.")
Future (projected) P/S of the market segment - Neuro
Athira Pharma is a biotech company developing small-molecule drugs to restore neural connections and treat neurodegenerative diseases such as Alzheimer's. Its approach is aimed at brain regeneration. This chart shows how the market views the risky but potentially huge success of its therapy compared to other companies.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772643578481 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
This demonstrates the general investor sentiment toward the treatment of neurodegenerative diseases. For Athira Pharma, a company working on Alzheimer's disease treatments, this is an indicator of faith in a scientific breakthrough. Market optimism is enabling it to attract the massive funding needed for research in this critically important, yet highly risky, field.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772643578490 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Athira Pharma Inc.
Athira Pharma is a biopharmaceutical company developing small-molecule therapies to restore neural health and slow neurodegeneration, particularly in Alzheimer's disease. This chart reflects revenue from grants and partnerships. Future revenue growth will depend on the success of clinical trials and the commercialization of its innovative approaches.
Sales of companies in the market segment - Neuro
Athira Pharma is a biotech company developing therapies to restore brain function in neurodegenerative diseases, including Alzheimer's disease. This chart reflects activity in the neuroscience sector. Athira's approach targets neuronal regeneration, one of the most advanced and promising areas in the industry.
Overall market sales
Athira Pharma, Inc. is developing treatments for neurodegenerative diseases such as Alzheimer's. Its development is entirely dependent on the success of clinical trials. The overall economic environment, shown in this chart, influences the influx of venture capital into the biotech sector to fund breakthrough research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Athira Pharma Inc.
Athira Pharma is a late-stage clinical development biotech focused on treating neurodegenerative diseases such as Alzheimer's disease. The company's future depends on the success of its clinical trials. This chart reflects analysts' confidence in Athira's scientific approach and the huge potential market for effective Alzheimer's therapy.
%20sales%20of%20the%20company%20Athira%20Pharma%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Athira-Pharma-Inc.&v=1772643578604 "Schedule of future (projected) sales of the company Athira Pharma Inc.")
Future (projected) sales of companies in the market segment - Neuro
Athira Pharma develops treatments for neurodegenerative diseases such as Alzheimer's. This chart illustrates expectations for the neuroscience sector. It reflects the enormous market potential and the high risks associated with finding an effective therapy for one of the most complex diseases of our time.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772643578669 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
Athira Pharma, Inc. is a late-stage biopharmaceutical company focused on treating neurodegenerative diseases such as Alzheimer's. Its future depends on the success of its trials. This graph, reflecting the state of the economy, influences investor risk appetite, which is critical for funding such ambitious and long-term projects.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772643578692 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Athira Pharma Inc.
Athira Pharma is developing drugs to combat neurodegenerative diseases such as Alzheimer's. This chart shows the scale of investment in solving one of the most complex medical problems. Negative values represent necessary research expenditures that, if successful, could yield enormous returns.
Market segment marginality - Neuro
Athira Pharma is developing therapies for neurodegenerative diseases such as Alzheimer's. For a research-stage biopharmaceutical company, this chart serves as an important indicator. It shows the average profitability in the sector, demonstrating the potential profitability Athira is aiming for if its clinical programs are successful.
Market marginality as a whole
Athira Pharma is a clinical-stage biotech company focused on restoring brain function in neurodegenerative diseases. This gross margin curve does not impact its operations. Its potential value lies in its scientific developments. Success depends on clinical trial data, not stock market performance.
Employees in the company, segment and market as a whole
Number of employees in the company Athira Pharma Inc.
Athira Pharma is a company developing treatments for neurodegenerative diseases such as Alzheimer's. This graph shows a small team of scientists and clinicians. Their size reflects their focus on research and clinical trials, where each specialist plays a key role.
Share of the company's employees Athira Pharma Inc. within the market segment - Neuro
Athira Pharma is working to restore neural connections to treat neurodegenerative diseases such as Alzheimer's. This chart shows the percentage of leading scientists in the field of neuroregeneration that the company attracts. It reflects its concentration of unique scientific expertise aimed at solving one of the most complex challenges in modern medicine.
Number of employees in the market segment - Neuro
Athira Pharma is a clinical-stage biotech company developing therapies to restore brain function in neurodegenerative diseases such as Alzheimer's. This chart illustrates how companies at the forefront of science are seeking breakthrough solutions to the most complex healthcare challenges, creating a demand for elite scientists.
Number of employees in the market as a whole
Athira Pharma is also focused on neuroscience, and its example highlights the competition for talent in this field. The overall employment growth, visible in this graph, is fueled by investments in breakthrough technologies. The demand for top scientific talent at companies like Athira is driving the development of education and raising the bar for the entire market.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Athira Pharma Inc. (ATHA)
Athira Pharma is a clinical-stage biotech company specializing in neurodegenerative diseases such as Alzheimer's. This chart represents a pure intellectual capital valuation. The company's value is based on the potential of its scientific platform. The chart shows how highly the market values these potential breakthrough drugs per scientist.
%20of%20the%20company%20Athira%20Pharma%20Inc.%20(ATHA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Athira-Pharma-Inc.-ATHA&v=1772643578944 "Chart of market capitalization per employee (in thousands of dollars) of the company Athira Pharma Inc. (ATHA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Athira Pharma also works in the complex field of neurodegenerative diseases. The company's value is almost entirely concentrated in its research and development, led by its team of scientists. This chart shows the premium the market is willing to pay for the expertise of each Athira employee compared to their peers. This is an indicator of trust in their scientific approach and potential breakthroughs.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772643578956 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Athira Pharma, Inc. is a late-stage clinical-stage biopharmaceutical company developing treatments for neurodegenerative diseases. This chart shows the estimated contribution of one employee, illustrating the market's expectations for a scientific breakthrough.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772643578975 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Athira Pharma Inc. (ATHA)
Athira Pharma is a biotech company working on Alzheimer's disease treatments. This is one of the most complex and capital-intensive areas of R&D. This chart shows the company's enormous per-employee burn rate. It reflects how much the company is burning through on each scientist in the race to develop a potential blockbuster.
%20Chart%20Athira%20Pharma%20Inc.%20(ATHA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Athira-Pharma-Inc.-ATHA&v=1772643578989 "Company Profit Per Employee (in thousands of dollars) Chart Athira Pharma Inc. (ATHA)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Athira Pharma is a clinical-stage biotech company focused on restoring brain function in neurodegenerative diseases such as Alzheimer's. Its value lies in its intellectual property and scientific team. This chart shows how R&D investments shape potential future profit per employee, which is typical for science-intensive startups.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772643579021 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Athira Pharma (ATHA) is a clinical-stage biotech company developing therapies to restore neural connections in neurodegenerative diseases such as Alzheimer's. It's an R&D company. This chart shows the market's standard profitability per employee. For ATHA (which is currently investing in R&D), this is a benchmark: if successful, their IP will generate profit per employee.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772643579034 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Athira Pharma Inc. (ATHA)
Athira Pharma is a biotech company focused on treating neurodegenerative diseases like Alzheimer's. This graph reflects the long and risky road ahead in biotech. The current numbers are small, but they lay the foundation for a future where one successful drug could change everything.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Athira-Pharma-Inc.-ATHA&v=1772643579068 "Sales chart per company employee Athira Pharma Inc. (ATHA)")
Sales per employee in the market segment - Neuro
Athira Pharma is a biotech company working on treatments for neurodegenerative diseases such as Alzheimer's. The company is in the R&D stage. This chart shows the average revenue per employee in this segment. It serves as a productivity benchmark for commercial pharmaceutical companies and helps evaluate the effectiveness of Athira's scientific team.
Sales per employee for the market as a whole
Athira Pharma is a clinical-stage biotech company developing therapies for neurodegenerative diseases such as Alzheimer's. The company has no commercial revenue. This metric currently doesn't reflect its value, as the entire team is focused on clinical trials rather than sales.
Short shares by company, segment and market as a whole
Shares shorted by company Athira Pharma Inc. (ATHA)
Athira Pharma is a biotech company trying to win the toughest race yet: developing a cure for Alzheimer's disease. The sector is a "graveyard" for investments. The company has also been through a data scandal. This chart shows bearish bets that their drug will fail in trials, like 99% of other Alzheimer's drugs.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Athira-Pharma-Inc.-ATHA&v=1772643579120 "Short Shares Chart for the Company Athira Pharma Inc. (ATHA)")
Shares shorted by market segment - Neuro
Athira Pharma, Inc. is a clinical-stage biotech company working to restore brain function and treat neurodegenerative diseases, primarily Alzheimer's disease. This chart shows the overall short position in the neuroscience-focused biotech sector. Its rise reflects investor skepticism about the success of Alzheimer's treatments, where almost all have failed.
Shares shorted by the overall market
Athira Pharma is a biotech company working on Alzheimer's disease. It's the "holy grail" of R&D, but also a "graveyard" for investors. This chart illustrates the overall market pessimism. When fear mounts, investors flee the riskiest areas. Athira shares are selling off, fearing trial failure and enormous costs.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Athira Pharma Inc. (ATHA)
This chart shows the tragedy of Athira Pharma. The company was developing a promising Alzheimer's drug. Early data showed "overheating" (above 70). However, a scandal involving possible falsification of research data and the subsequent failure of a key trial plunged the oscillator into deep "oversold" territory (below 30), from which it has been unable to recover.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Athira-Pharma-Inc.-ATHA&v=1772643579154 "RSI 14 indicator chart for the company's stock Athira Pharma Inc. (ATHA)")
RSI 14 Market Segment - Neuro
Athira (ATHA) is a biotech company and an Alzheimer's hunter. Their specialty is small molecules that repair (HGF/MET) signaling pathways in the brain. The Neuro (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It helps us understand: is ATHA's volatility due to their Alzheimer's hype, or is the entire biotech sector overheated?
RSI 14 for the overall market
Athira Pharma (ATHA) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ATHA (Athira Pharma Inc.)
Athira Pharma (ATHA) is a biotech company developing drugs to restore neural connections in neurodegenerative diseases such as Alzheimer's. This chart shows the average price target, reflecting analysts' speculative belief in its unique scientific approach.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ATHA-Athira-Pharma-Inc.&v=1772643579228 "A chart showing analyst consensus forecasts for the expected stock price. ATHA (Athira Pharma Inc.)")
The difference between the consensus estimate and the actual stock price ATHA (Athira Pharma Inc.)
Athira Pharma is a biotech company developing drugs (HGF/MET) to restore neural connections in Alzheimer's disease. This chart shows the difference between the market valuation and the consensus forecast. It reveals whether experts believe in this complex yet groundbreaking scientific hypothesis.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ATHA-Athira-Pharma-Inc.&v=1772643579234 "A chart showing the difference between the consensus forecast and the actual stock price. ATHA (Athira Pharma Inc.)")
Analyst consensus forecast for stock prices by market segment - Neuro
Athira Pharma is a biotech company going all-in. It's developing a new approach (HGF/MET) to treat Alzheimer's disease, the "holy grail" of neuroscience. This chart reflects analyst expectations across the neuroscience sector, demonstrating whether experts believe a breakthrough can be achieved in the R&D "graveyard."
Analysts' consensus forecast for the overall market share price
Athira Pharma is a biotech company working on one of the most challenging problems: treating Alzheimer's disease by "restoring" neural connections. This chart shows the overall "risk appetite" in the market. For Athira, which operates in the riskiest area of medicine, overall market optimism (a rising chart) is critical to funding multi-year trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Athira Pharma Inc.
Athira Pharma is a biotech company focused on brain restoration. Their R&D (HGF/MET) is focused not on purification (like Biogen's), but on neuronal regeneration for the treatment of Alzheimer's and Parkinson's. This chart is a clear indicator of their (very risky) R&D. It reflects their progress in clinical trials and their (controversial) path to FDA approval.
AKIMA Market Segment Index - Neuro
Athira Pharma (ATHA) is a biotech company developing drugs to treat neurodegenerative diseases (Alzheimer's, Parkinson's). Their approach (HGF/MET) is aimed at regenerating and protecting neurons. The chart shows the average index for the segment, helping investors assess how Athira's risks and potential compare to the average in the neuroscience sector.
The AKIM Index for the overall market
Athira Pharma is a biotech company developing small molecules for neuron restoration in Alzheimer's disease and other dementias. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this scientific story, searching for a way forward after clinical setbacks, compares to overall trends.
